详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Case Report: Active tuberculosis infection in CAR T-cell recipients post CAR T-cell therapy: a retrospective case series

76| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [2]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China. [3]Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [4]Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

出处：

DOI：

ISSN：

关键词： immunocompromised host immunity tuberculosis extrapulmonary tuberculosis chimeric antigen receptor T-cell

摘要：

High response rates in B-cell malignancies have been achieved with chimeric antigen receptor (CAR) T-cell therapy. Emerging reports indicate a risk of active tuberculosis (TB) with novel immunotherapy for tumors. However, studies of TB in patients post CAR T-cell therapy are limited. In this case series study, we describe five patients with active TB post CD19/CD22 target CAR T-cell therapy alone or following autologous stem cell transplantation (ASCT). One of the patients developed active TB within the first 30 days post CAR T-cell therapy, and fever was the dominant presenting symptom; extrapulmonary manifestations of active TB were common in the other four patients and manifested after the first 30 days of CAR T-cell therapy. Four of the five patients improved with anti-TB treatment, but one patient with isoniazid resistance died of central nervous system TB infection. Our study provides the first series report of active TB following CD19/CD22 target CAR T-cell therapy.Copyright © 2023 Zhang, Huang, Zheng, Zhang, Wan, Wei and Cao.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区医学

小类 | 2 区微生物学 2 区免疫学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区免疫学 2 区微生物学

JCR分区：

出版当年[2021]版：

Q1 MICROBIOLOGY Q2 IMMUNOLOGY

最新[2023]版：

Q1 MICROBIOLOGY Q2 IMMUNOLOGY

影响因子： 4.6 最新[2023版] 5.1 最新五年平均 6.073 出版当年[2021版] 6.34 出版当年五年平均 5.293 出版前一年[2020版] 5.7 出版后一年[2022版]

第一作者：

第一作者单位： [1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [2]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.

通讯作者：

通讯机构： [1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [2]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Effects of cryopreservation on chimeric antigen receptor T cell functions [2]Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas [3]Patients' experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study [4]Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy [5]CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations [6]Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients [7]Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma [8]The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook [9]Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future [10]A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells